Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Payables (2018 - 2025)

Arcturus Therapeutics Holdings' Payables history spans 8 years, with the latest figure at $4.2 million for Q4 2025.

  • For Q4 2025, Payables fell 41.13% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $4.2 million, down 41.13%, while the annual FY2025 figure was $4.2 million, 41.13% down from the prior year.
  • Payables reached $4.2 million in Q4 2025 per ARCT's latest filing, down from $5.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $19.3 million in Q1 2023 to a low of $4.2 million in Q4 2025.
  • Average Payables over 5 years is $9.9 million, with a median of $9.6 million recorded in 2022.
  • Peak YoY movement for Payables: surged 136.36% in 2023, then tumbled 52.73% in 2024.
  • A 5-year view of Payables shows it stood at $10.1 million in 2021, then decreased by 25.94% to $7.4 million in 2022, then dropped by 29.13% to $5.3 million in 2023, then skyrocketed by 36.28% to $7.2 million in 2024, then tumbled by 41.13% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Payables are $4.2 million (Q4 2025), $5.5 million (Q3 2025), and $10.6 million (Q2 2025).